234 related articles for article (PubMed ID: 24222836)
1. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.
Hess CN; Schulte PJ; Newby LK; Steg PG; Dalby AJ; Schweiger MJ; Lewis BS; Armstrong PW; Califf RM; van de Werf F; Harrington RA
Eur Heart J Acute Cardiovasc Care; 2013 Sep; 2(3):246-55. PubMed ID: 24222836
[TBL] [Abstract][Full Text] [Related]
2. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
[TBL] [Abstract][Full Text] [Related]
3. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
[TBL] [Abstract][Full Text] [Related]
4. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.
Toleva O; Westerhout CM; Senaratne MP; Bode C; Lindroos M; Sulimov VA; Montalescot G; Newby LK; Giugliano RP; Van de Werf F; Armstrong PW
Catheter Cardiovasc Interv; 2014 Nov; 84(6):934-42. PubMed ID: 24976083
[TBL] [Abstract][Full Text] [Related]
5. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK
Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952
[TBL] [Abstract][Full Text] [Related]
6. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
Lopes RD; White JA; Tricoci P; White HD; Armstrong PW; Braunwald E; Giugliano RP; Harrington RA; Lewis BS; Brogan GX; Gibson CM; Califf RM; Newby LK
Int J Cardiol; 2013 Sep; 167(6):2580-7. PubMed ID: 22795720
[TBL] [Abstract][Full Text] [Related]
7. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
Le May MR; Wells GA; Glover CA; So DY; Froeschl M; Marquis JF; O'Brien ER; Turek M; Thomas A; Kass M; Jadhav S; Labinaz M
Circ Cardiovasc Interv; 2009 Aug; 2(4):330-8. PubMed ID: 20031736
[TBL] [Abstract][Full Text] [Related]
8. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial.
Kaul P; Tanguay JF; Newby LK; Hochman JS; Westerhout CM; Califf RM; Tricoci P; Gibson CM; Giugliano RP; Harrington RA; Van de Werf F; Armstrong PW
Am Heart J; 2013 Oct; 166(4):723-8. PubMed ID: 24093853
[TBL] [Abstract][Full Text] [Related]
9. Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.
Wilczynski M; Wybraniec MT; Milewski K; Sanak M; Wita K; Buldak Ł; Kondys M; Buszman P; Bochenek A
J Cardiovasc Surg (Torino); 2016 Feb; 57(1):100-10. PubMed ID: 26771733
[TBL] [Abstract][Full Text] [Related]
10. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
[TBL] [Abstract][Full Text] [Related]
11. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Fung AY; Saw J; Starovoytov A; Densem C; Jokhi P; Walsh SJ; Fox RS; Humphries KH; Aymong E; Ricci DR; Webb JG; Hamburger JN; Carere RG; Buller CE
J Am Coll Cardiol; 2009 Mar; 53(10):837-45. PubMed ID: 19264239
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial.
Abtan J; Wiviott SD; Sorbets E; Popovic B; Elbez Y; Mehta SR; Sabatine MS; Bode C; Pollack CV; Cohen M; Moccetti T; Laanmets P; Faxon D; Okreglicki A; Ducrocq G; Steg PG;
Arch Cardiovasc Dis; 2021 Mar; 114(3):187-196. PubMed ID: 33518473
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.
Vavalle JP; Clare R; Chiswell K; Rao SV; Petersen JL; Kleiman NS; Mahaffey KW; Wang TY
JACC Cardiovasc Interv; 2013 Jul; 6(7):709-17. PubMed ID: 23866183
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
[TBL] [Abstract][Full Text] [Related]
17. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM;
JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880
[TBL] [Abstract][Full Text] [Related]
18. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
[TBL] [Abstract][Full Text] [Related]
19. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.
Farhan S; Clare RM; Jarai R; Giugliano RP; Lokhnygina Y; Harrington RA; Kristin Newby L; Huber K
Int J Cardiol; 2017 Apr; 232():264-270. PubMed ID: 28089149
[TBL] [Abstract][Full Text] [Related]
20. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Goa KL; Noble S
Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
